Insulet touts real-world data for Omnipod insulin management tech

Insulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes. The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data […]

Artificial pancreas: These companies are racing to make one

Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in our newest Medical Design & Outsourcing video. (And for a deeper dive, check out our recent roundup of companies in the

These big medtech names performed the best in early 2017

Fink Densford, Associate Editor and Chris Newmarker, Managing Editor This year so far has been an especially good one for medical device company stocks. More than four-fifths of the world’s 100 largest medical device companies saw their stock values increase during the first quarter of 2017 – about half enjoyed double-digit percentage increases, according to an analysis

Pages: 1 2 3 4 5 6 7 8

7 companies in the race to make an artificial pancreas

Over 50 years ago, scientists discovered the ability to externally control blood glucose regulation for individuals with type 1 diabetes. Since then, researchers in the field of diabetes management have dreamt of creating a closed-loop system – a combined glucose sensor, control algorithm and insulin infusion device – to effectively act as an “artificial pancreas”

Pages: 1 2 3 4 5 6 7 8 9

The top medtech stories of early 2017

The new Trump administration and Republican Congress – and all the accompanying change and uncertainty –is the major story for the medical device industry. But there are many other medtech stories worth noting from the first quarter of 2017. There was an FDA warning over Abbott’s Absorb bioresorbable stent, a continued spate of M&A deals, a

Pages: 1 2 3 4 5 6

Insulet taps ATS Automation Tooling for planned U.S. plant, beefs up executive suite

Insulet (NSDQ:PODD) said today it inked a 5-year deal with ATS Automation Tooling Systems to construct an automated manufacturing assembly line for its products and announced a pair of new executive appointments. Billerica, Mass.-based Insulet said it expects the contract with ATS to cost approximately $35 million. ATS is slated to design, build and install manufacturing